Published in Drug Week, October 20th, 2006
According to scientists in the United States, "We report that administration of celecoxib, a specific cyclooxygenase-2 (COX-2) inhibitor, in combination with a dendritic cell-based cancer vaccine significantly augments vaccine efficacy in reducing primary tumor burden, preventing metastasis, and increasing survival. This combination treatment was tested in MMTV-PyV NIT mice that develop spontaneous mammary gland tumors with metastasis to the lungs and bone marrow."
"Improved vaccine potency was associated with an increase in tumor-specific CTLs," stated Gargi D. Basu and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.